Can you stay on weight loss injections forever — or is there a time limit?

The big misconception: that these medicines are only a short-term fix

A lot of people approach weight loss injections assuming there will be a natural endpoint, a course you complete, like antibiotics. It is an understandable assumption, and letting it go gently is worth doing early, because the biology tells a different story.

Obesity is a long-term condition driven by hormones, genetics and environment. Tirzepatide and semaglutide work by influencing appetite-regulating hormones that are dysregulated in people living with obesity. When the medicine is stopped, those hormonal signals return to their previous state, and weight often comes back. This was shown clearly in trial extension data for semaglutide, where participants who discontinued regained much of the weight they had lost. The NHS describes this as a known and expected outcome, not an indication that the treatment failed.

So the question of whether you can stay on these injections for a long time shifts quickly into whether continued treatment remains appropriate for you specifically. That is a prescriber's call, made in light of your progress, your side-effect profile and your overall health picture. You can read more about how duration decisions work in practice on our page covering how long you should stay on weight loss injections.

What the UK licences and NICE guidance say

The UK marketing authorisation for both Mounjaro and Wegovy does not impose a fixed maximum duration. Clinically, treatment can continue for as long as the benefits outweigh the risks and the prescriber judges it appropriate. That is broadly the same position as for other long-term medicines, such as those for blood pressure or cholesterol.

Where things get more specific is within NHS commissioning. NICE's guidance on semaglutide (TA875) recommends it for a maximum of two years when funded through NHS specialist weight management services. If fewer than five per cent of body weight is lost after six months at the maintenance dose, continuing is not recommended. These are NHS funding conditions, not a ceiling on private prescribing under the licensed indication.

NICE's recommendation for tirzepatide (TA1026) similarly includes a review point if adequate weight loss has not been achieved, but does not impose a fixed two-year cap. For people accessing treatment privately through a regulated pharmacy, the licensed indication and your prescriber's clinical judgement govern how long treatment continues. Our overview of treatment duration breaks this down in more detail.

What ongoing treatment actually looks like

Long-term use is not the same as unsupervised use. Whether you are six months in or three years in, a prescriber should be reviewing your weight, your health and any side effects before each repeat. At nume, that review happens before every prescription is issued, a named clinician reads your update, not software, and the prescription is only authorised when it remains appropriate.

Side effects tend to be most noticeable in the early weeks of treatment or after a dose increase, typically settling as your body adjusts. Common ones include nausea, changes to appetite and digestion, and occasional headaches, as detailed on the NHS tirzepatide medicines page. For most people, these ease over time rather than worsening, which is relevant when thinking about long-term tolerability.

If you are considering these treatments for the first time or thinking about whether to carry on, it helps to understand the broader landscape of weight loss injections available in the UK and what they involve practically. The cost of ongoing private treatment is something many people factor in too; for context on that side of things, our treatment page is the right place to look.

What happens if you stop, and when stopping makes sense

Stopping is sometimes the right choice. Treatment reviews might conclude that the goals of treatment have been met within a wider lifestyle programme, that side effects are not settling as expected, or that personal circumstances have changed. Pregnancy, for instance, means treatment should stop, as these medicines are not recommended during pregnancy or while breastfeeding.

When people do stop, weight regain is common. Research published as part of the STEP programme found that much of the weight lost during treatment gradually returned after stopping. This is not a reason to stay on treatment indefinitely if your prescriber advises otherwise, but it is useful context for thinking about what stopping means practically, and for having an honest conversation about it.

Our page on whether you have to stay on weight loss injections forever covers the stopping decision in more depth, including what the evidence says about maintaining results. If you are living with obesity and are weighing up whether these medicines are right for you long-term, that context matters from the start, and our guide to whether you have to be on weight loss injections forever is a good place to explore that question before you begin.